Skip to main content

Advertisement

Table 2 SARAH trial assessment schedule

From: Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial

Visits Enrolment/randomisation D0 D15 M1 M2 M3 M4 M5 M6 M7 M8 M9 End of participation
Identification X             
Verification of selection criteria X             
Consent signature X             
Initial assessment – history X             
CT scan X    X   X    X    X X
CT perfusion X    X   X    X     
Laboratory tests X X X X X X X X X X X X X
Classification X    X X X X X X X X X X
Clinical examination     X X X X X X X X X X
Quality of life questionnaires X    X   X    X    X X
Preparatory angiography   X            
Scintigraphy   X            
RE   X            
Start of sorafenib treatment   X            
Retreatment*     X X X X X X X X X  
Cancer progression monitoring     X X X X X X X X X X
Sorafenib monitoring     X X X X X X X X X X
Concomitant medication     X X X X X X X X X X
Adverse events     X X X X X X X X X X
  1. *Timing of retreatment depends upon type of retreatment (see text). CT, computed tomography; D, day; M, month; RE, radioembolisation.